Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Target Healthcare disposes of nine UK care homes, completes debt refinancing

(Sharecast News) - Real estate investment trust Target Healthcare said on Thursday that it has disposed of nine UK care homes above carrying value to an institutional purchaser. Target Healthcare said the "landmark transaction" of £85.9m represented its largest disposal since IPO and was transacted at a 11.6% premium to the group's carrying value as of 30 June. The sale price represented an implied net initial yield of 5.24%.

The FTSE 250-listed firm stated the "highly accretive disposal", which represents 537 beds and roughly 8.3% of the group's overall portfolio value, reduces its exposure to its current largest tenant, HC‑One/Ideal Carehomes, from around 16.0% to approximately 8.8% based on rental income.

Completion of the disposal, which was unconditional and expected to take place on 22 October, will result in an annualised ungeared internal rate of return in excess of 11%.

Target Healthcare also announced the completion of its debt refinancing, agreeing to improved terms with The Royal Bank of Scotland plc and HSBC UK, and revealed that its investment manager, Target Fund Managers, had appointed Alastair Murray as chief financial officer, replacing Gordon Bland.

Additionally, Target said it has "a strong pipeline of near-term assets" at a net initial yield of roughly 6%, made up of a combination of accretive investment opportunities, including high-quality, strongly performing existing UK care homes, all with en suite wet-rooms and new purpose-built forward-funded assets.

Target stated the acquisition of the first of the existing care homes in the pipeline was expected to take place in November. Executing on the rest of this pipeline of assets was expected to utilise the proceeds from the disposal, as well as making efficient use of its new debt facilities.

As of 0830 BST, Target Healthcare shares were up 1.27% at 95.60p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.